Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in western populations, and is closely associated with features of the metabolic syndrome. The burden of disease is set to rise exponentially, and this is further compounded by the lack of good medications. In addition, these patients tend to have multiple comorbidities that may not be adequately managed. In this article, we review the biological basis of potential therapies in nonalcoholic steatohepatitis (NASH), the current drugs being tested in clinical trials, as well some practical considerations in managing patients in the clinic.? 2019 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd.
展开▼
机译：非酒精性脂肪肝病（NAFLD）是西方人群中最常见的慢性肝病，与代谢综合征的特征密切相关。疾病的负担被设置为呈指数上升，这将通过缺乏良好的药物进一步复杂化。此外，这些患者往往具有多种可充分管理的合并症。在本文中，我们审查了在临床试验中进行了目前在临床试验中测试的当前药物的潜在疗法的生物学基础，以及在临床中管理患者的实际考虑。？ 2019年的作者。 John Wiley＆Sons Ltd.出版的内分泌，糖尿病和新陈代谢
展开▼
